IBJNews

Lilly drug beats Roche’s Avastin in advanced colon cancer

Bloomberg News
September 30, 2013
Keywords
Back to TopCommentsE-mailPrintBookmark and Share

Cancer drug Erbitux extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin, manufacturer Merck KGaA of Germany said Saturday.

Merck sells the medicine outside North America. Indianapolis-based Eli Lilly and  Co. and New York-based Bristol-Myers Squibb Co. are the partners for the drug in the United States. Erbitux generated sales for Merck of $1.2 billion last year, while. Lilly realized about $400 million in revenue from the drug in 2012.

In a trial among 342 patients with advanced colon cancer lacking certain genetic mutations, those receiving Erbitux had a median survival of 33.1 months, compared with 25.6 months for those treated with Avastin, according to a Merck statement of data presented at a cancer conference in Amsterdam. Both drugs were combined with chemotherapy.

The findings suggest that Erbitux, already approved in Europe as a treatment for patients with so-called KRAS wild-type tumors, may have a role in a sub-group of patients with so-called RAS wild-type cancer. Merck, based in Darmstadt, Germany, is studying the results of two other trials for evidence of the same trend, with a view to seeking regulatory approval in Europe for the drug in patients with RAS wild-type cancer.

“Of course, we are highly interested to get the right treatment to the right patients,” Oliver Kisker, head of clinical development at Merck’s Serono unit, said. The additional 7.5 months is “very impressive, very interesting.”

Erbitux and Avastin are so-called monoclonal antibodies designed to block a protein that causes cancer cells to multiply. By coupling Erbitux or Avastin with a trio of cell-killing chemotherapy drugs, doctors aim both to stop tumors from growing and to shrink them.

Among the 16 percent of patients with a mutant form of RAS colon cancer, those who received Erbitux had a median overall survival of 20.3 months compared with 20.6 months for those who received Avastin, according to the Merck report.

The study missed its main goal of shrinking tumors more than Avastin did in patients with the mutant form of KRAS colon cancer, Merck said in June.

Lilly shares were down 14 cents Monday, to $50.36 each.

ADVERTISEMENT

  • good news
    I like hearing this news, if accurate, 7.5 months is a long time when one is facing death! Avastin has been tried on so many types of cancer, and it has seemed to provide very little to no benefit for any, and its side effects can be devastating. Unfortunately, Avastin cost so much to develop they won't just quit trying it and come up with a better cancer drug. Now it seems they will throw it at any cancer to see if it sticks.

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Hiking blocks to an office after fighting traffic is not logical. Having office buildings around the loop, 465 and in cities in surrounding counties is logical. In other words, counties around Indianapolis need office buildings like Keystone, Meridian, Michigan Road/College Park and then no need to go downtown. Financial, legal, professional businesses don't need the downtown when Carmel, Fishers, North Indy are building their own central office buildings close to the professionals. The more Hamilton, Boone county attract professionals, the less downtown is relevant. Highrises have no meaning if they don't have adequate parking for professionals and clients. Great for show, but not exactly downtown Chicago, no lakefront, no river to speak of, and no view from highrises of lake Michigan and the magnificent mile. Indianapolis has no view.

  2. "The car count, THE SERIES, THE RACING, THE RATINGS, THE ATTENDANCE< AND THE MANAGEMENT, EVERY season is sub-par." ______________ You're welcome!

  3. that it actually looked a lot like Sato v Franchitti @Houston. And judging from Dario's marble mouthed presentation providing "color", I'd say that he still suffers from his Dallara inflicted head injury._______Considering that the Formula E cars weren't going that quickly at that exact moment, that was impressive air time. But I guess we shouldn't be surprised, as Dallara is the only car builder that needs an FAA certification for their cars. But flying Dallaras aren't new. Just ask Dan Wheldon.

  4. Does anyone know how and where I can get involved and included?

  5. While the data supporting the success of educating our preschoolers is significant, the method of reaching this age group should be multi-faceted. Getting business involved in support of early childhood education is needed. But the ways for businesses to be involved are not just giving money to programs and services. Corporations and businesses educating their own workforce in the importance of sending a child to kindergarten prepared to learn is an alternative way that needs to be addressed. Helping parents prepare their children for school and be involved is a proven method for success. However, many parents are not sure how to help their children. The public is often led to think that preschool education happens only in schools, daycare, or learning centers but parents and other family members along with pediatricians, librarians, museums, etc. are valuable resources in educating our youngsters. When parents are informed through work lunch hour workshops in educating a young child, website exposure to exceptional teaching ideas that illustrate how to encourage learning for fun, media input, and directed community focus on early childhood that is when a difference will be seen. As a society we all need to look outside the normal paths of educating and reaching preschoolers. It is when methods of involving the most important adult in a child's life - a parent, that real success in educating our future workers will occur. The website www.ifnotyouwho.org is free and illustrates activities that are research-based, easy to follow and fun! Businesses should be encouraging their workers to tackle this issue and this website makes it easy for parents to be involved. The focus of preschool education should be to inspire all the adults in a preschooler's life to be aware of what they can do to prepare a child for their future life. Fortunately we now know best practices to prepare a child for a successful start to school. Is the business community ready to be involved in educating preschoolers when it becomes more than a donation but a challenge to their own workers?

ADVERTISEMENT